ClinicalTrials.gg
TerminatedNCT00956293SenatorUpdated Jun 6, 2014Results posted

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

A Phase 4 interventional study of Basiliximab and Enteric Coated Mycophenolic Acid (MPA) in Renal Transplantation, sponsored by Novartis Pharmaceuticals. Terminated at 9 sites in Germany. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2014-06-06.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was terminated
The study was terminated because the required sample size of 240-260 de novo senior renal transplant patients was not achieved within a reasonable time.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
207
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

This study wants to address whether a calcineurin-inhibitor (CNI)-free regimen six weeks after transplantation for Eurotransplant Senior Program (ESP) patients is as safe and well tolerated as standard treatment but optimizing immunosuppressive therapy with benefits in renal function, new-onset diabetes mellitus, cardiovascular risk, cancer and allograft nephropathy.

02

Conditions studied

  • Renal Transplantation
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.

Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving a primary kidney from a donor aged > 65 years
  • In the Eurotransplant Senior Program
  • Recipients of de novo cadaveric kidney transplants

Exclusion criteria

Exclusion criteria:

  • Multi-organ recipients (e.g., kidney and pancreas)
  • Patients receiving a kidney from a non-heart beating donor
  • Patients who are recipients of A-B-O incompatible transplants
  • Patients with already existing antibodies against the HLA-type of the receiving transplant
  • Patients who have received an drug within four weeks prior to study entry (Baseline visit 1)
  • Patients with thrombocytopenia, with an of \< 1,500/mm³ or leucopenia or \< 6 g/dL
  • Patients who are , , or surface antigen positive
  • Evidence of severe liver disease
  • Females at randomization who will be not considered

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Active comparator
    Control group

    During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group continued with a CNI-based regimen of MPA and CsA.

    Drug: Basiliximab · Drug: Enteric Coated Mycophenolic Acid (MPA) · Drug: Cyclosporin A (CsA) · Drug: Corticosteroids

  • Experimental
    Everolimus group

    During the pre-randomized treatment phase, all participants received a CNI-based regimen consisting of basiliximab, mycophenolic acid (MPA), cyclosporin A (CsA) and corticosteroids (optional). Upon randomization, participants in this group made a stepwise switch to a CNI-free regimen of everolimus and MPA.

    Drug: Basiliximab · Drug: Enteric Coated Mycophenolic Acid (MPA) · Drug: RAD001 · Drug: Cyclosporin A (CsA) · Drug: Corticosteroids

Interventions

  • On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.

    Also known as: Simulect

  • A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.

    Also known as: Myfortic

  • DrugRAD001

    Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).

    Also known as: RAD001, Certcian

  • Dosage was based according to blood level

    Also known as: Sandimmun Optoral

  • DrugCorticosteroids

    Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).

06

What researchers measure

Primary outcomes

  1. Renal Function by Glomerular Filtration Rate (GFR) Via Cockcroft-Gault Method

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Month 6

Secondary outcomes

  1. Renal Function by GFR Via Modification of Diet in Renal Diseases (MDRD) and Nankivell Method

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Month 6

  2. Renal Function by Serum Creatinine

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Months 6, 12, 24, 36, 48 and 60

  3. Biopsy Proven Acute Rejection (BPAR), Graft Loss and Death

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Months 6, 12, 24, 36, 48 and 60

  4. Occurrence of Treatment Failures

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Month 6

  5. Evolution of Renal Function (Creatinine Slope)

    The study was terminated prematurely and not powered for efficacy.

    Time frame: Week 7, Month 6

  6. CD25 Saturation on Lymphocytes

    Time frame: Month 6

  7. Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death

    Participants with adverse events (serious plus non-serious), serious adverse events and death were reported.

    Time frame: Months 6, 12, 24, 36, 48 and 60

  8. Renal Function by GFR Over Time

    Time frame: Months 12, 24, 36, 48 and 60

  9. Renal Function by Proteinuria

    Time frame: Months12, 24, 36, 48 and 60

07

Results

Posted May 12, 2014

Participant flow

The study consisted of a main period and a 54 month observation follow-up period. The main period included a pre-randomized treatment phase (6 weeks) and a randomized treatment phase (18 weeks). All randomized participants, who participated in the main period, were eligible for the follow-up period.

Main Period (Pre-randomization)
Participant flow — Main Period (Pre-randomization)
MilestoneControl GroupEverolimus GroupPre-randomized Group
Started00207
Enrolled safety set00203
Completed0077
Not completed00130
Withdrew: Not specified (data missing)001
Withdrew: Death001
Withdrew: Protocol violation001
Withdrew: Abnormal test procedure result002
Withdrew: Administrative problems006
Withdrew: Graft loss007
Withdrew: Withdrawal by subject0012
Withdrew: Lack of efficacy0020
Withdrew: Adverse event0036
Withdrew: Abnormal laboratory value0044
Main Period (Randomization)
Participant flow — Main Period (Randomization)
MilestoneControl GroupEverolimus GroupPre-randomized Group
Started24530
Full analysis set24510
Randomized safety set24510
Completed23260
Not completed1270
Withdrew: Abnormal laboratory value020
Withdrew: Lack of efficacy1100
Withdrew: Adverse event0150
Follow-up Period
Participant flow — Follow-up Period
MilestoneControl GroupEverolimus GroupPre-randomized Group
Started20320
Completed000
Not completed20320
Withdrew: Follow-up period was terminated.20320

Outcome measures

PrimaryRenal Function by Glomerular Filtration Rate (GFR) Via Cockcroft-Gault Method

The study was terminated prematurely and not powered for efficacy.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryRenal Function by GFR Via Modification of Diet in Renal Diseases (MDRD) and Nankivell Method

The study was terminated prematurely and not powered for efficacy.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryRenal Function by Serum Creatinine

The study was terminated prematurely and not powered for efficacy.

Time frame:
Months 6, 12, 24, 36, 48 and 60

No measurements were reported for this outcome.

SecondaryBiopsy Proven Acute Rejection (BPAR), Graft Loss and Death

The study was terminated prematurely and not powered for efficacy.

Time frame:
Months 6, 12, 24, 36, 48 and 60

No measurements were reported for this outcome.

SecondaryOccurrence of Treatment Failures

The study was terminated prematurely and not powered for efficacy.

Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryEvolution of Renal Function (Creatinine Slope)

The study was terminated prematurely and not powered for efficacy.

Time frame:
Week 7, Month 6

No measurements were reported for this outcome.

SecondaryCD25 Saturation on Lymphocytes
Time frame:
Month 6

No measurements were reported for this outcome.

SecondaryNumber of Participants Who Experienced Adverse Events, Serious Adverse Events and Death

Participants with adverse events (serious plus non-serious), serious adverse events and death were reported.

Time frame:
Months 6, 12, 24, 36, 48 and 60
Reported as:
Number · Participants
Number of Participants Who Experienced Adverse Events, Serious Adverse Events and Death
ParticipantsControl GroupEverolimus Group
Adverse events (serious and non-serious)2150
Serious adverse events1128
Deaths00
SecondaryRenal Function by GFR Over Time
Time frame:
Months 12, 24, 36, 48 and 60

No measurements were reported for this outcome.

SecondaryRenal Function by Proteinuria
Time frame:
Months12, 24, 36, 48 and 60

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Control Goup—11/24 (45.8%)15/24 (62.5%)
Everolimus Group—28/51 (54.9%)50/51 (98%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventControl GoupEverolimus Group
BLOOD CREATININE INCREASEDInvestigations4/245/51
URINARY TRACT INFECTIONInfections and infestations3/245/51
INFECTIONInfections and infestations2/241/51
PNEUMONIAInfections and infestations2/244/51
LEUKOPENIABlood and lymphatic system disorders0/243/51
ANAEMIABlood and lymphatic system disorders1/242/51
MITRAL VALVE INCOMPETENCECardiac disorders1/240/51
TRANSPLANT REJECTIONImmune system disorders1/240/51
HEPATIC CYST INFECTIONInfections and infestations1/240/51
ANURIARenal and urinary disorders1/240/51
Most frequent other events
Showing 10 of 27
Most frequent other events
EventControl GoupEverolimus Group
URINARY TRACT INFECTIONInfections and infestations6/2422/51
LEUKOPENIABlood and lymphatic system disorders4/2420/51
OEDEMA PERIPHERALGeneral disorders7/2413/51
HYPOKALAEMIAMetabolism and nutrition disorders0/2412/51
DIARRHOEAGastrointestinal disorders0/2410/51
APHTHOUS STOMATITISGastrointestinal disorders0/249/51
PYREXIAGeneral disorders4/245/51
PROTEINURIARenal and urinary disorders0/248/51
DYSPNOEARespiratory, thoracic and mediastinal disorders3/243/51
HYPERTENSIONVascular disorders3/246/51

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Control GroupEverolimus GroupTotal
Mean69.3 ± 3.168.4 ± 3.368.7 ± 3.3
Sex: Female, Male
Sex: Female, Male(Participants)Control GroupEverolimus GroupTotal
Female82634
Male162541
08

Study locations

9 sites
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Kaiserslautern, 67655, Germany
  • Novartis Investigative Site
    Koeln-Merheim, 51109, Germany
  • Novartis Investigative Site
    München, 81377, Germany
09

References and documents

Publications

  • Brakemeier S, Arns W, Lehner F, Witzke O, Vonend O, Sommerer C, Muhlfeld A, Rath T, Schuhmann R, Zukunft B, Kroeger I, Porstner M, Budde K. Everolimus in de novo kidney transplant recipients participating in the Eurotransplant senior program: Results of a prospective randomized multicenter study (SENATOR). PLoS One. 2019 Sep 19;14(9):e0222730. doi: 10.1371/journal.pone.0222730. eCollection 2019. PubMed 31536556 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in May 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2009
First posted
Aug 11, 2009
Start
Jul 2009
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
May 12, 2014
Last update
Jun 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00956293
Responsible party
Sponsor
First posted
Aug 11, 2009
Start date
Jul 2009
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
May 12, 2014
Last update
Jun 6, 2014

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Everolimus

Start the discussion